Business Segments Summit Therapeutics Inc.
Stocks
SMMT
US86627T1088
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-09-16 EDT
|
5-day change | 1st Jan Change | ||
| 17.30 USD | -0.57% |
|
-1.37% | -1.09% |
| 09-09 | Summit Therapeutics Shares Rise After Upgrade From Jefferies | MT |
| 09-09 | Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Drug Development | 1.81M | 705K | - | - | - | |||||
Total Assets | 113M | 664M | 203M | 436M | 751M | |||||
Interest Expense | -281K | -4.4M | -16.46M | -8.69M | - | |||||
Income Tax Expense | - | - | - | - | - | |||||
CAPEX | -306K | -624K | -128K | -139K | -657K | |||||
EBT | -88.6M | -78.78M | -615M | -221M | -1.08B | |||||
D&A | 2.46M | 2.51M | 2.05M | 89K | 146K | |||||
Operating Income | -86.19M | -72.09M | -610M | -226M | - | |||||
Net Income | -88.6M | -78.78M | -615M | -221M | -1.08B |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Latin America | 1.81M | 705K | - | - | - | |||||
United States | - | - | - | - | - | |||||
Total Assets | 722K | 2.56M | 5.25M | 436M | 751M | |||||
Europe | - | - | - | - | - | |||||
Total Assets | 2.76M | 2.52M | 808K | - | - |
- Stock Market
- Stocks
- SMMT Stock
- Financials Summit Therapeutics Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
